Pharmacogenetic screening of n-acetyltransferase 2, thiopurine s-methyltransferase, and 5,10-methylene-tetrahydrofolate reductase polymorphisms in northwestern mexicans

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 5, 2011, Pages 351-355

  Ramos, Marco A ^a   Mares, Rosa E ^a   Avalos, Erick D ^a   Hernández, Anaid ^a   Hernández, Rogelio ^a   Lameda, Rodrigo ^a   Malváez, Analleli E ^a   Rodríguez, Carla A ^a   Rodríguez, Rosario ^a  

^a UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ARYLAMINE ACETYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE;

ADULT; ALLELE; ARTICLE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; PHARMACOGENETICS; POPULATION GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); METHYLTRANSFERASES; MEXICO; PHARMACOGENETICS; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 79956072630     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0216     Document Type: Article

References (40)

1. Adkins RM (2004) Comparison of the accuracy of methods of computational haplotype inference using a large empirical dataset. BMC Genet 5:22.
2. Aguirre-Rodríguez AA, Martínez-de Villarreal LE, Velazco- Campos MR, et al. (2008) Prevalence of polymorphism in the MTHFR gene in a population sample from Nuevo Leon, Mexico. Salud Pública Mex 50:5-7.
3. Agúndez JA, Golka K, Martínez C, et al. (2008) Unraveling ambiguous NAT2 genotyping data. Clin Chem 54:1390-1394.
4. Cascorbi I, Drakoulis N, Brockmöller J, et al. (1995) Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57:581-592.
5. Celtikci B, Lawrance AK, Wu Q, et al. (2009) Methotrexateinced apoptosis is enhanced by altered expression of methylenetetrahydrofolate reductase. Anticancer Drugs 20:787-793.
6. Cerda-Flores RM, Villalobos-Torres MC, Barrera-Saldaña HA, et al. (2002) Genetic admixture in three Mexican Mestizo populations based on D1S80 and HLA-DQA1 loci. Am J Hum Biol 14:257-263. (Pubitemid 34232679)
7. Crettol S, Petrovic N, Murray M (2010) Pharmacogenetics of phase I and phase II drug metabolism. Curr Pharm Des 16:204-219.
8. Daar AS, Singer PA (2005) Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet 6:241-216.
9. De Mattia E, Toffoli G (2009) C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidinebased therapy personalisation. Eur J Cancer 45:1333-1351.
10. Duley JA, Florin TH (2008) Azathioprine: when less is more. J Gastroenterol Hepatol 23:1317-1319.
11. Frosst P, Blom HJ, Milos R, et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113.
12. Gross M, Kruisselbrink T, Anderson K, et al. (1999) Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 8:683-692. (Pubitemid 30064536)
13. Hein DW, Boukouvala S, Grant DM, et al. (2008) Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogen Genomics 18:367-368. (Pubitemid 351367530)
14. Jorge-Nebert LF, Eichelbaum M, Griese EU, et al. (2002) Analysis of six SNP of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics 12:39-48. (Pubitemid 34112241)
15. Juárez-Velázquez R, Canto P, Canto-Cetina T, et al. (2010) Analysis of polymorphisms in genes (AGT, MTHFR, GPIIIa, and GSTP1) associated with hypertension, thrombophilia and oxidative stress in Mestizo and Amerindian populations of México. Dis Markers 28:323-331.
16. Kim SH, Kim SH, Bahn JW, et al. (2009) Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 10:1767-1779.
17. Kim YI (2005) 5,10-Methylenetetrahydrofolate reductase polymorphisms and pharmacogenetics: a new role of single nucleotide polymorphisms in the folate metabolic pathway in human health and disease. Nutr Rev 63:398-407.
18. Kim YI (2009) Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol 5:523-542.
19. Kirchheiner J, Fuhr U, Brockmöller J (2005) Pharmacogeneticsbased therapeutic recommendations-ready for clinical practice? Nat Rev Drug Discov 4:639-647. (Pubitemid 41149757)
20. Lee SY, Lee KA, Ki CS, et al. (2002) Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem 48:775-777.
21. Li N, Stephens M (2003) Modelling linkage disequilibrium, and identifying recombination hotspots using SNP data. Genetics 165:2213-2233. (Pubitemid 38040302)
22. Okumura K, Kita T, Chikazawa S, et al. (1997) Genotyping of Nacetylation polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther 61:509-517. (Pubitemid 27261755)
23. Pavlovic S (2009) TPMT gene polymorphisms: on the doorstep of personalized medicine. Indian J Med Res 129:478-480.
24. Roden DM, George AL Jr. (2002) The genetic basis of variability in drug responses. Nat Rev Drug Discov 1:37-44. (Pubitemid 37361402)
25. Rodríguez-Guillén Mdel R, Torres-Sánchez L, Chen J, et al. (2009) Maternal MTHFR polymorphisms and risk of spontaneous abortion. Salud Pública Mex 51:19-25.
26. Roy PD, Majumder M, Roy B (2008) Pharmacogenomics of anti- TB drugs-related hepatotoxicity. Pharmacogenomics 9:311-321. (Pubitemid 351803934)
27. Sahasranaman S, Howard D, Roy S (2008) Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 64:753-767.
28. Sekine A, Saito S, Iida A, et al. (2001) Identification of singlenucleotide polymorphisms (SNP) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population. J Hum Genet 46:314-319. (Pubitemid 32524628)
29. Sim E, Walters K, Boukouvala S (2008) Arylamine N-acetyltransferases: from structure to function. Drug Metab Rev 40:479-510. (Pubitemid 352019961)
30. Taja-Chayeb L, Vidal-Millán S, Gutiérrez O, et al. (2008) Thiopurine S-methyltransferase gene (TPMT) polymorphisms in a Mexican population of healthy individuals and leukemic patients. Med Oncol 25:56-62.
31. Toffoli G, De Mattia E (2008) Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics 9:1195-1206.
32. Urano W, Taniguchi A, Yamanaka H, et al. (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12:183-190. (Pubitemid 34596782)
33. van der Put NM, Gabreëls F, Stevens EM, et al. (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62:1044-1051. (Pubitemid 28199004)
34. Walker K, Ginsberg G, Hattis D, et al. (2009) Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev 12:440-472.
35. Wang L, Weinshilboum R (2006) Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25:1629-1638.
36. Weber WW(1999) Populations and genetic polymorphisms. Mol Diagn 4:299-307. (Pubitemid 30036369)
37. Weinshilboum R, Wang L (2004) Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 3:739-748. (Pubitemid 39242826)
38. Yates CR, Krynetski EY, Loennechen T, et al. (1997) Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-614. (Pubitemid 27172187)
39. Zhou S (2006) Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol 1:119-128.
40. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89-295.